B

대봉엘에스

078140KOSDAQ의약품 제조업

59.3 / 100

Reference Date: 2026-07-24

Financial Score25.5 / 40
News Sentiment17.8 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Rose 5.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Daebong LS, established in 1986, operates across medical beauty and bio sectors, developing safe and effective products aligned with its mission to provide solutions for a healthier, more beautiful life. Key offerings include respiratory treatments, hypertension drugs, and functional cosmetic materials, with consolidated revenue reaching 1,021 billion KRW in 2025, reflecting an 8.6% year-over-year growth.

Number of Employees

138people

Average Salary

54.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
8.40Industry Average 11.236.5Point

Lower than industry avg (good)

PBR
0.49Industry Average 0.815.5Point

Lower than industry avg (good)

ROE
7.05Industry Average 4.015.5Point

1.8x industry avg (good)

Debt Ratio
39.82Industry Average 12.430.0Point

3.2x industry avg (risky)

Trend 2023~20258.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲7.9% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲59.6% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 5.8% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 3Neutral 2Negative 0Average Sentiment Score 71

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 7,720Won52-week high 14,04052-week low 7,070
1-month return4.0Point

1m +5.61% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral기타경영사항(자율공시) (국책과제 선정 (산업용 미생물 기반 루테인 대량생산 생물제조공정및 소재 상용화 기술 개발))2026-07-06